Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

2.160 +0.080 (+3.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Purple Biotech Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Purple Biotech (PPBT) Stock Is Getting Hammered
Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. 
Via Benzinga
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom
As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026. 
Via Stocktwits
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Is Purple Biotech Stock Trading Higher On Monday?
Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes. 
Via Benzinga
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
From Purple Biotech Ltd.
Via GlobeNewswire
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS